AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01874145
Drug: GA 40 mg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glatiramer acetate (GA) 40 mg/mL subcutaneous (SC) injection, is a single-use pre-filled syringe (PFS) containing 1.0 ml of a clear, colorless to slightly yellow, sterile, non-pyrogenic solution.
Trial: NCT03840993
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: over 16 weeks
Trial: NCT00551954
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet t.i.d.
Trial: NCT01602900
Drug: GSK356278
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational Medicinal Product
Trial: NCT02233699
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00004250
Drug: isolated limb perfusion
RxNorm normalized name: ISOLATE
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00022399
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400mg PO twice daily for 4-6 weeks up to 8 hours prior to prostatectomy.
Trial: NCT00402337
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, once daily
Trial: NCT04226495
Drug: Sufentanil Infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-operative sufentanil infusion
Trial: NCT04226495
Drug: Sufentanil Bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-operative sufentanil bolus
Trial: NCT01779492
Drug: GL2907
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once a day
Trial: NCT02016365
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg/day (100 mg twice daily, orally) for 4 weeks with a pause of 2 weeks in combination with UDCA
Trial: NCT00475514
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02596217
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC injection (stage 1)
Trial: NCT02596217
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion (stage 2)
Trial: NCT02009332
Drug: ABI-009
RxNorm normalized name: PICEA ABIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABI-009 is a nanoparticle albumin-bound (nab®) formulation of the mammalian Target of Rapamycin ( mTOR) inhibitor, sirolimus. Specifically, ABI-009 is a sterile lyophilized powder of albumin-bound sirolimus nanoparticles with a mean particle size of less than 100 nm.
Trial: NCT04276649
Drug: Caltrate
RxNorm normalized name: Caltrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in supplementary group were received with Caltrate 0.6 g/d and Mesalazine 4g/d orally at least 12 months, and those in non-supplementary only take Mesalazine 4g/d.
Trial: NCT01714609
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator: Placebo
Trial: NCT00795639
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitaxsentan Placebo = 1 tablet administered orally, once daily
Trial: NCT01074996
Drug: S-1 plus Leucovorin
RxNorm normalized name: (S)-Leucovorin
DrugBank: (6R)-Folinic acid (DB03256)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 40-60mg bid, days 1-14 , every 3 weeks Leucovorin 25mg bid , days 1-14 , every 3 weeks
Trial: NCT03796364
Drug: standard SRILI treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the control group were treated with current routine radiation pneumonia. At week 2, 4, 6, 12, 24, 36, 52, lung functional and blood oxygen saturation was measured, chest CT and the St. George Respiratory Questionnaire (SGRQ) were assessed for quality of life at week 12, 24, 52 and before treatment; collecting the related observation indexes of patients; primary endpoint; recrudescence rate of RP; secondary endpoints; remission rate of RP and incidence rate of RF; incidence rate of RF; number of acute exacerbations and quality of life.
Trial: NCT00034944
Drug: Comparator: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03283059
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Tablet: P.O. tid
Trial: NCT04747951
Drug: consolidation chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of oxaliplatin (130 mg/m2 over 2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 3 courses, 3 weeks per course
Trial: NCT04631705
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of DZIF-10c diluent as placebo
Trial: NCT04631705
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of sterile normal saline (NaCl 0.9%) as placebo
Trial: NCT04747951
Drug: adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of l-LV (400 mg/m2) and oxaliplatin (85 mg/ m2) by intravenous infusion over 2 h, followed by rapid intravenous infusion (iv) of 5-FU (400 mg/m2) and then slow infusion (civ) of 5-FU (2400 mg/m2 over 46 h), is repeated every 2 weeks for 6-12 cycles
Trial: NCT00649402
Drug: Lotrel® Capsules 10 mg/20 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10/20mg, single dose fed
Trial: NCT03374722
Drug: Opioids
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanically ventilated critically ill patients who receive continuous opioid infusion for more than 24 hours will be observed for withdrawal symptoms when rate of opioid infusion is disrupted or decreased
Trial: NCT04480333
Drug: Drug: NA-831 - 0.20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NA-831 in nanoparticle inhalation formulation
Trial: NCT04480333
Drug: Placebo- 0.20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in nanoparticle inhalation formulation
Trial: NCT04480333
Drug: Drug: GS-5734 - 1.00 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GS-5734 in nanoparticle inhaled formulation
Trial: NCT04480333
Drug: Placebo- 1.00 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in nanoparticle inhalation formulation
Trial: NCT04480333
Drug: Drug: GS-5734 - 2.00 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GS-5734 in nanoparticle inhaled formulation
Trial: NCT04480333
Drug: Placebo- 2.00 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in nanoparticle inhaled formulation
Trial: NCT01318356
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic therapy will consist of doxycycline once daily 200 mg (in 1 capsule) for 24 weeks. Patients will be monitored 4, 8, 16 and 26 weeks after start for side effects (rash, liver enzymes). Antibiotics will be stopped in case of side effects or pregnancy.
Trial: NCT01318356
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the placebo group will receive once daily 1 placebo capsule identical in appearance to the doxycycline for 24 weeks and have the same visits and monitoring for side effects as the patients randomized to doxycycline (Patients will be monitored 4, 8, 16 and 26 weeks)
Trial: NCT00555022
Drug: GSK1160724
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1160724 will be available with dosing strengths of 10, 50 and 125 micrograms/blister for inhalation using the DISKUS inhaler.
Trial: NCT00000448
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo is a simulated or otherwise medically ineffectual treatment for a disease or other medical condition intended to deceive the recipient.
Trial: NCT00555022
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive placebo.
Trial: NCT02597465
Drug: SPARC1507
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The administered dose is calculated based on the BSA calculated for the subject on Day 1 of the Cycle
Trial: NCT02597465
Drug: Reference1507
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigators choice including chemotherapy or supportive therapy
Trial: NCT04392830
Drug: ALZ002 DS
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT04392830
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00688922
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Take an initial dose of pravastatin to start as 10mg/day, which is the recommended initial dose by Health, Labour and Welfare Ministry of Japan, and a diet counseling.
Trial: NCT01886781
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micro-crystalline cellulose powder, identical taste, texture and appearance
Trial: NCT00952523
Drug: Tretinoin Facial Gel
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A marketed facial gel containing Tretinoin 0.04% is applied to one side of the face daily for three weeks.
Trial: NCT04534114
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to BAY2976217 will be injected subcutaneously.
Trial: NCT04463004
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion
Trial: NCT04247256
Drug: FOLFIRI Protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI standard treatment on day 5 to 7 (both days included) of a 14 day period. repeated bi-weekly
Trial: NCT04236921
Drug: DopaSnap®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: immediate release CD/LD 25/100mg; Riverside Pharmaceuticals Corporation, USA
Trial: NCT00399763
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half of participants are randomized to placebo plus individual cognitive behavioral therapy targeting substance use disorder
Trial: NCT00240292
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02205801
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00457639
Drug: Cholic Acid
RxNorm normalized name: Cholic Acid
DrugBank: Cholic Acid (DB02659)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsules of active Cholic Acid or matching placebo, total dose is 15 mg/kg per day, maximum dose of 1500 mg per day, taken PO, BID.
Trial: NCT00103857
Drug: Comparator: MK0431 50 mg b.i.d. (b.i.d. = twice daily)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK0431 oral tablets will be started on Day 1 at 50 mg q.d. (q.d. = once daily) and increased after one week to a stable dose of 50 mg b.i.d. (b.i.d. = twice daily) Patients will continue to take MK0431 50 mg b.i.d. for the remainder of the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and during the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
Trial: NCT00103857
Drug: Comparator: MK0431 100 mg q.d. (q.d. = once daily)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK0431 oral tablets will be started on Day 1 as two 50 mg tablets (100 mg q.d.) (q.d. = once daily) and continued at this dose throughout the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
Trial: NCT02600767
Drug: Artemether-lumefantrine combination
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is the sole arm in this study and it is the use of the standard combination therapy for treatment of P. falciparum malaria.
Trial: NCT02716766
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PO
Trial: NCT02647255
Drug: Methylprednisolone pulse
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: methylprednisolone 7-15mg/kg/d 3 times, Qd. or Qod
Trial: NCT00237809
Drug: D-serine
RxNorm normalized name: D-Serine
DrugBank: D-Serine (DB03929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-serine (30 mg/kg)
Trial: NCT00901979
Drug: LCQ908A
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00237809
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo D-serine Drug
Trial: NCT00901979
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02613052
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL of normal saline agitated prior to IV administration
Trial: NCT01858623
Drug: Losartan/hydrochlorothiazide
RxNorm normalized name: losartan/hydrochlorothiazide 100 mg-25 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00777309
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo is provided as a capsule
Trial: NCT02488733
Drug: CMT
RxNorm normalized name: CMT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMT consists in the use of the best treatment strategies, involving pharmacological and dietary therapies, lifestyle and physical activity, with the aim of both glycemic control and weight loss, administered on the basis of the current guidelines of the American Diabetes Association (ADA)\[50\] and determined on an individual basis \[52\].The administration of such pharmacological and non-pharmacological therapies will be adjusted in accordance with the algorithms of the ADA .
Trial: NCT03639545
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients receive for 12 weeks.
Trial: NCT02751125
Drug: BCP with autologous mesenchymal stem cells (MSC).
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmentation of narrow alveolar ridge with BCP and MSC
Trial: NCT02433899
Drug: 2.0% Mepivacaine + 1:100.000 epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regional block
Trial: NCT02626494
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 days before or after, placebo will be administered analogously as described with n-AC. Placebo will be given according to a double-blind, placebo-controlled cross-over design. Subjects receive 3 doses of placebo over 2 consecutive days (total dose=4800mg; individual doses=2x1200mg, 1x2400mg). Subjects will take 2 first doses (à 1200mg) of placebo 1 day before scanning (one in the morning, one in the evening), and the last dose (2400mg) 1h prior to scanning, with 12 hours dosing intervals in between. Preparation and blinding of placebo capsules will be performed by the Kantonsapotheke Zürich according to the guidelines of Good Manufacturing Practice.
Trial: NCT04093050
Drug: Vasostrict Injectable Product
RxNorm normalized name: Vasostrict Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasostrict® (vasopressin injection, USP)
Trial: NCT02076594
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Film coated tablets
Trial: NCT01429285
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attending administers any IV opioid in any dose he chooses
Trial: NCT02923349
Drug: INCAGN01949
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial cohort dose of INCAGN01949 monotherapy at the protocol-defined starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose will be taken forward into expansion cohorts.
Trial: NCT02191540
Drug: Abnoba Viscum F 20mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravesical instillation of five amples of AbnobaViscum® F20mg and 0.9% normal saline into the pleural space
Trial: NCT00504205
Drug: multitargeted receptor tyrosine kinase inhibitor MP470
RxNorm normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06245902
Drug: Naltrexone and Acetaminophen
RxNorm normalized name: bupropion and naltrexone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone plus acetaminophen
Trial: NCT06245902
Drug: Naltrexone and Acetaminophen-High Dose
RxNorm normalized name: bupropion and naltrexone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexon (high dose) plus acetaminophen
Trial: NCT06245902
Drug: Acetaminophen Alone
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen Alone plus Placebo
Trial: NCT02735707
Drug: Standard course macrolide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard course of macrolide therapy, discontinued between study day 3 and the end of study day 5.~The dosing of and route of administration is not protocolised, the following guidance is provided:~* Initial IV administration of a macrolide is strongly preferred~* The preferred IV macrolide is azithromycin, but IV clarithromycin may be substituted.~* The preferred enteral macrolide is azithromycin, but enteral clarithromycin or roxithromycin may be substituted.
Trial: NCT00115167
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Q4W
Trial: NCT03824340
Drug: Doxycycline before ICSI
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extra medication (Doxycycline ) group before ICSI :,women who will receive more medications (Doxycycline ) before starting the ICSI process
Trial: NCT01692834
Drug: Sandimmune® Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01692834
Drug: NeuroSTAT®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02735707
Drug: Fixed-duration Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 50mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days.~Note: this intervention is now closed.
Trial: NCT02735707
Drug: Shock-dependent hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 50mg IV hydrocortisone every 6 hours while the patient is in septic shock
Trial: NCT02735707
Drug: Fixed-duration higher dose Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 100mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days.~Note: this intervention was only available to patients with suspected or proven COVID-19 and is now closed.
Trial: NCT00255242
Drug: Simvastatin treatment for 28 days
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg / day
Trial: NCT00882375
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered using novel NRT user instructions
Trial: NCT02735707
Drug: Local standard venous thromboprophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard venous thromboprophylaxis that complies with local guidelines or usual practice will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first.~Note: this intervention is now closed.
Trial: NCT02735707
Drug: Therapeutic dose anticoagulation
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be administered either low molecular weight heparin (LMWH) or unfractionated heparin (UFH) to achieve systemic anticoagulation. Either agent may be used and the same patient may be switched between UFH and LMWH at the discretion of the treating clinician.~Note: this intervention is now closed.
Trial: NCT02735707
Drug: Intermediate dose thromboprophylaxis
RxNorm normalized name: Prevotella intermedia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate dose thromboprophylaxis will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first. Dosing is outlined in the relevant protocol documents for this domain.
Trial: NCT01451840
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bolus dose of intravenous remifentanil 0.25 mcg/kg given once before emergence of general anesthesia
Trial: NCT02735707
Drug: Continuation of therapeutic dose anticoagulation
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients already receiving therapeutic dose anticoagulation at the time of randomisation to this intervention will be administered either unfractionated heparin by IV infusion or low-molecular weight heparin to achieve systemic anticoagulation according to local practice for acute VTE treatment for 14 days following randomisation or until hospital discharge, whichever occurs first.~Note: this intervention is now closed.
Trial: NCT00267865
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6000 mg/m\^2 will be administered by intravenous infusion over 4 hours after confirming that the recipient patients urine pH is within the range greater than or equal to 7 to less than or equal to 8, and urine output is greater than or equal to 100 mL/hour.
Trial: NCT00267865
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leucovorin calcium doses will be administered orally or by short intravenous (IV) infusion over 15 minutes
Trial: NCT00796575
Drug: CS-8080
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-8080 1mg tablets, 3 tablets administered 1 times per day